New frontiers in the treatment of systemic juvenile idiopathic arthritis [version 1; referees: 2 approved]
Systemic juvenile idiopathic arthritis (sJIA) and its most significant complication, macrophage activation syndrome (MAS), have traditionally been treated with steroids and non-steroidal anti-inflammatory medications. However, the introduction of biologic medications that inhibit specific cytokines,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2017-06-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | https://f1000research.com/articles/6-971/v1 |
| _version_ | 1818506048500137984 |
|---|---|
| author | Susan Canny Elizabeth Mellins |
| author_facet | Susan Canny Elizabeth Mellins |
| author_sort | Susan Canny |
| collection | DOAJ |
| description | Systemic juvenile idiopathic arthritis (sJIA) and its most significant complication, macrophage activation syndrome (MAS), have traditionally been treated with steroids and non-steroidal anti-inflammatory medications. However, the introduction of biologic medications that inhibit specific cytokines, such interleukins 1 and 6, has changed the treatment paradigm for sJIA patients. In this review, we discuss the therapies currently used in the treatment of sJIA as well as novel targets and approaches under consideration, including mesenchymal stromal cell therapy and JAK inhibitors. We also discuss targeting cytokines that have been implicated in MAS, such as interferon gamma and interleukin 18. |
| first_indexed | 2024-12-10T21:59:09Z |
| format | Article |
| id | doaj.art-59ea3eeefcf3470fad64e3e26a5f6c8e |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-10T21:59:09Z |
| publishDate | 2017-06-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-59ea3eeefcf3470fad64e3e26a5f6c8e2022-12-22T01:31:57ZengF1000 Research LtdF1000Research2046-14022017-06-01610.12688/f1000research.11327.112227New frontiers in the treatment of systemic juvenile idiopathic arthritis [version 1; referees: 2 approved]Susan Canny0Elizabeth Mellins1Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USADepartment of Pediatrics, Program in Immunology, Stanford University, Stanford, CA, USASystemic juvenile idiopathic arthritis (sJIA) and its most significant complication, macrophage activation syndrome (MAS), have traditionally been treated with steroids and non-steroidal anti-inflammatory medications. However, the introduction of biologic medications that inhibit specific cytokines, such interleukins 1 and 6, has changed the treatment paradigm for sJIA patients. In this review, we discuss the therapies currently used in the treatment of sJIA as well as novel targets and approaches under consideration, including mesenchymal stromal cell therapy and JAK inhibitors. We also discuss targeting cytokines that have been implicated in MAS, such as interferon gamma and interleukin 18.https://f1000research.com/articles/6-971/v1Clinical ImmunologyDrug Discovery & DesignImmune & Inflammatory Rheumatic Diseases (incl. Arthritis)Innate ImmunityLeukocyte Signaling & Gene Expression |
| spellingShingle | Susan Canny Elizabeth Mellins New frontiers in the treatment of systemic juvenile idiopathic arthritis [version 1; referees: 2 approved] F1000Research Clinical Immunology Drug Discovery & Design Immune & Inflammatory Rheumatic Diseases (incl. Arthritis) Innate Immunity Leukocyte Signaling & Gene Expression |
| title | New frontiers in the treatment of systemic juvenile idiopathic arthritis [version 1; referees: 2 approved] |
| title_full | New frontiers in the treatment of systemic juvenile idiopathic arthritis [version 1; referees: 2 approved] |
| title_fullStr | New frontiers in the treatment of systemic juvenile idiopathic arthritis [version 1; referees: 2 approved] |
| title_full_unstemmed | New frontiers in the treatment of systemic juvenile idiopathic arthritis [version 1; referees: 2 approved] |
| title_short | New frontiers in the treatment of systemic juvenile idiopathic arthritis [version 1; referees: 2 approved] |
| title_sort | new frontiers in the treatment of systemic juvenile idiopathic arthritis version 1 referees 2 approved |
| topic | Clinical Immunology Drug Discovery & Design Immune & Inflammatory Rheumatic Diseases (incl. Arthritis) Innate Immunity Leukocyte Signaling & Gene Expression |
| url | https://f1000research.com/articles/6-971/v1 |
| work_keys_str_mv | AT susancanny newfrontiersinthetreatmentofsystemicjuvenileidiopathicarthritisversion1referees2approved AT elizabethmellins newfrontiersinthetreatmentofsystemicjuvenileidiopathicarthritisversion1referees2approved |